6bc5d616-670c-4778-a769-d5b64fc51d8e
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 77.7522245037646
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.500
- E2F_TARGETS+0.490
- G2M_CHECKPOINT+0.450
- MYC_TARGETS_V1+0.390
- UNFOLDED_PROTEIN_RESPONSE+0.320
- CHOLESTEROL_HOMEOSTASIS+0.300
- DNA_REPAIR+0.300
- PANCREAS_BETA_CELLS+0.230
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.220
- MITOTIC_SPINDLE+0.180
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- INTERFERON_ALPHA_RESPONSE-0.410
- ALLOGRAFT_REJECTION-0.330
- INTERFERON_GAMMA_RESPONSE-0.330
- KRAS_SIGNALING_UP-0.320
- HEDGEHOG_SIGNALING-0.310
- ANGIOGENESIS-0.290
- COMPLEMENT-0.260
- COAGULATION-0.240
- MYOGENESIS-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | c6c161fd-9f0a-4ad5-96ba-b9ce811348fc | — | — | 0.906 |
| 2 | TCGA-LA-A446-01A-21R-A24Z-07 | — | cohortSQ2 | 0.873 |
| 3 | MDT-AP-0843 | Med | Medulloblastoma | 0.871 |
| 4 | TCGA-85-8354-01A-31R-2326-07 | — | cohortSQ2 | 0.865 |
| 5 | 20020032.TNBC | — | E | 0.864 |
| 6 | a8ce7460-8ccd-4638-a854-55c4068af6ec | — | — | 0.856 |
| 7 | SRR8518170 | — | E | 0.853 |
| 8 | TCGA-AO-A0J7-01A-11R-A034-07 | — | B | 0.853 |
| 9 | TCGA-94-8035-01A-11R-2247-07 | — | cohortSQ1 | 0.852 |
| 10 | MNG531 | — | — | 0.852 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.490 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.390 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.300 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.230 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.220 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.180 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.150 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.140 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.090 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.080 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.080 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.060 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.060 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.050 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.050 | Idelalisib | — uncovered |